Brief: Huadong Medicine Says Unit, Arcutis Biotherapeutics' Drug Gets US FDA Approval
18/12/2023 09:15
Dec 18 (Reuters) - Huadong Medicine Co Ltd 000963.SZ :
* SAYS UNIT AND ARCUTIS BIOTHERAPEUTICS INC' SEBORRHEIC
DERMATITIS
DRUG ZORYVE GETS APPROVAL FROM US FDA
Source text
Further company coverage: 000963.SZ
(Reporting by Hong Kong Newsroom)
((Ethan.Wang@thomsonreuters.com;))
Recent news on Arcutis Biotherapeutics
See all newsBrief: Arcutis Canada Przoryve Cream 0.05% Receives Health Canada Approval For Atopic Dermatitis
Arcutis Biotherapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Arcutis Q2 revenue rises on demand for ZORYVE, lifts 2026 sales outlook
Arcutis Biotherapeutics Inc expected to post earnings of 4 cents a share - Earnings Preview
Brief: Arcutis Biotherapeutics reports inducement grants under Nasdaq listing rule 5635(C)(4